Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...

During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

Patients with early breast cancer treated with presurgical endocrine therapy or chemotherapy plus Herceptin and Perjeta ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

HER2 overexpression in patients with nonmuscle-invasive bladder cancer independently predicts worse response to intravesical BCG therapy.

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less ...

The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer ... outcome was measured by the invasive disease-free survival ...

As if a limited initial FDA approval was not bad enough, AstraZeneca’s Truqap has recorded a pivotal trial flop that could ...

Giredestrant has a stronger anti-proliferative effect than anastrozole in patients with estrogen receptor-positive, HER2-negative, previously untreated early breast cancer, a new study suggests.

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. /PRNewswire/ -- USA News Group – Cancer rates are rising glob ...